ROCHE POSICOR FIRST-LINE HYPERTENSION/ANGINA USE CLEARS FDA ADVISORY CMTE. WITH PRECAUTIONS ABOUT ECG CHANGES; POSICOR CHF TRIAL TO CONCLUDE IN MID-1998
Executive Summary
Roche's Posicor (mibefradil) has a "success rate" in reducing blood pressure below 90 mm Hg in about two-thirds of patients given the highest recommended dose, the company maintained before FDA's Cardiovascular & Renal Drugs Advisory Committee Feb. 28.